News Daily News When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters Ticagrelor may be limited by cost and a twice-daily formulation, but it lowers both ischemic and bleeding risk vs clopidogrel. Yael L. Maxwell March 21, 2024
Presentation THT 2024 Shock-Phenotype Matching Using Real-World Evidence: A New Paradigm for Prospective Enrollment in Clinical Trials of Acute MCS Devices in Cardiogenic Shock Presenter: James Schurr March 06, 2024
Presentation THT 2024 A Novel Study Design, Termed Molecular Triangulation, That Leverages Biologic Similarities Across Seemingly Different Shock Phenotypes In Order to Identify Novel Druggable Targets and Pathophysiologic Mechanisms. Presenter: Thomas Hanff March 06, 2024
Presentation THT 2024 DPP3-Based Biotherapy in Cardiogenic Shock Presenter: Mahir Karakas March 06, 2024
News Daily News Intravascular Imaging Lowers Risk of MACE at 1 Year in Left Main PCI By Michael O'Riordan March 26, 2024
News Daily News When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters By Yael L. Maxwell March 21, 2024
News Daily News Abiomed Recalls Labeling for Left-Sided Impella Pumps: FDA By Caitlin E. Cox March 21, 2024